



泰福生技首次響應台灣賑災行動 攜手支持花蓮災後重建

Tanvex Takes First Step in Local Philanthropy – Supporting Hualien Post-Disaster Recovery

台北，台灣，2025 年 10 月 14 日－泰福生技股份有限公司（以下簡稱「泰福生技」，台灣證券交易所股票代碼：6541）針對近日花蓮光復鄉因颱風造成的嚴重災情，泰福生技本於企業社會責任，響應衛生福利部發起的賑災募捐行動，號召台灣員工共同參與，員工參與比例達 11%，展現團隊對在地社會的關懷與行動力。

Taipei, Taiwan – October 14th, 2025 – Tanvex BioPharma Inc. (TWSE: 6541, “Tanvex”) has demonstrated its commitment to corporate social responsibility by encouraging employees in Taiwan to support a disaster relief fundraising campaign launched by the Ministry of Health and Welfare, in response to the recent severe typhoon damage in Guangfu Township, Hualien County. The initiative received an enthusiastic response, with 11% of employees participating.

此次行動亦是泰福與保瑞生技正式合併後，泰福首次參與台灣的公益回饋活動，象徵公司邁向在地深耕的重要一步。相關捐款已由保瑞藥業統籌捐贈予衛生福利部「0923 花蓮馬太鞍溪堰塞湖災害專案」，以支持災區重建與緊急救助工作。

This marks Tanvex’s first participation in a local philanthropic initiative since officially merging with Bora Biologics, representing an important step toward deeper community engagement. The donation was made through the Bora Group to support the Ministry of Health and Welfare’s “0923 Hualien Mataian Creek Landslide Disaster Relief Project,” contributing to reconstruction and emergency relief efforts.

泰福表示，作為一家外商背景、近年在台上市的生技公司，能夠投入本地賑災行動，對公司而言意義深遠。未來將持續以具體行動深化與台灣社會的連結，攜手打造更有韌性的未來。

As a multinational biopharmaceutical company newly listed in Taiwan, this initiative holds special significance for Tanvex. It reflects the company’s commitment to actively engaging with the local community and lays the foundation for continued involvement and shared resilience in the future.

關於泰福生技

泰福生技股份有限公司（台灣證券交易所：6541）成立於2011年，其使命是通過使生物製劑更加經濟實惠且提高可取得性來革新全球醫藥產業。多年來，泰福生技在生物製劑開發和製造方面不斷精進專業知識，最終成功實現了第一個產品的商業化。隨著另一個生物製劑許可申請（BLA）正等待美國FDA批准，泰福生技的發展歷程體現了對卓越、創新的堅定承諾，以及改善患者醫藥服務的熱忱。泰福生技致力於推進醫療保健，這促使其以「Bora Biologics」的品牌擴展了作為CDMO的能力。整併前的保瑞

生技已擁有超過70批成功的cGMP製造記錄，為全球生物製藥公司提供靈活、全面的一站式服務方案，在確保品質的同時、提高時間和成本效率。通過利用其全球CDMO能力、美國FDA核准通過的先進設施，以及在生物製劑開發和製造方面的深厚專業知識，保瑞生技為其客戶確保了高效且有效的市場進入途徑。

About Tanvex and Bora Biologics

Tanvex BioPharma, Inc. (TWSE: 6541), was founded in 2011 with a mission to revolutionize the healthcare industry by making biologics more affordable and accessible to patients. Over the years, Tanvex has honed its expertise in biologics development and manufacturing, culminating in the successful commercialization of our first product. With another Biological License Application (BLA) pending U.S. FDA approval, Tanvex's journey is characterized by an unwavering commitment to excellence, innovation, and a passion for improving patient care.

Tanvex's commitment to advancing healthcare has led to the expansion of its capabilities as a CDMO under the name Bora Biologics. With a proven track record of over 100 successful cGMP manufacturing batches, Bora Biologics provides agile, comprehensive end-to-end solutions that enhance time and cost efficiencies for biopharma companies worldwide. By leveraging its global CDMO capabilities, state-of-the-art, FDA-registered facility in the U.S., and deep expertise in biologics development and manufacturing, Bora Biologics ensures efficient and effective pathways to market for its clients.

【新聞聯絡人】

泰福生技 樂君儀 Angela Luan: angela.luan@tanvex.com 0922-407094